<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03226847</url>
  </required_header>
  <id_info>
    <org_study_id>17-584</org_study_id>
    <nct_id>NCT03226847</nct_id>
  </id_info>
  <brief_title>Pulmonary Vein Isolation in Athletes</brief_title>
  <official_title>Pulmonary Vein Isolation in Athletes: Effects on Peak Performance and Pulmonary Vein Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary vein isolation (PVI) has become a common and effective treatment for paroxysmal and&#xD;
      persistent atrial fibrillation (AF), particularly in patients with drug-refractory disease.&#xD;
      Intense endurance exercise is a known risk factor for atrial fibrillation. In general, these&#xD;
      athletes poorly tolerate most common antiarrhythmic drugs used for atrial fibrillation&#xD;
      control and often PVI is recommended for durable management. While the efficacy of PVI in&#xD;
      athletes is similar to the general AF population, some athletes with lone atrial fibrillation&#xD;
      report a reduction in subjective exertional capacity following PVI, despite maintenance of&#xD;
      sinus rhythm and absence of pulmonary vein stenosis on imaging. The investigators hypothesize&#xD;
      that PVI may alter pulmonary vein function and affect peak exercise performance.&#xD;
&#xD;
      The investigators propose a small, prospective study of endurance athletes undergoing antral&#xD;
      PVI for treatment of lone atrial fibrillation. Peak metabolic performance and pulmonary vein&#xD;
      function will be assessed pre- and post-PVI by metabolic stress testing and cardiac MRI,&#xD;
      respectively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endurance athletes with paroxysmal or persistent atrial fibrillation undergoing primary&#xD;
      pulmonary vein isolation will be prospectively enrolled prior to PVI.&#xD;
&#xD;
      Patients will undergo metabolic exercise stress testing as well as resting CMR 1-4 weeks&#xD;
      prior to PVI. Metabolic stress testing and CMR will be repeated at 6 month follow-up. Quality&#xD;
      of life questionnaires will also be collected at pre- and post-PVI visits. Metabolic&#xD;
      treadmill stress testing will follow standard protocol and measure hemodynamics with&#xD;
      escalating metabolic output and characterize peak exercise capacity (METs) and oxygen&#xD;
      consumption (VO2 max).&#xD;
&#xD;
      CMR evaluation will include standard anatomic imaging of pulmonary vein and left atrial&#xD;
      anatomy at rest. Additional cine CMR sequences willbe included for focused evaluation of&#xD;
      dynamic pulmonary vein cross-sectional area. 3D navigator whole heart imaging and MRA (single&#xD;
      gadolinium dose) will be obtained to measure pulmonary vein flow. CMR sequences to&#xD;
      characterize left atrial function, including phasic volumes and emptying fractions (total,&#xD;
      passive, active) will also be performed.&#xD;
&#xD;
      Data on heart rate variability will additionally be collected at pre- and post-PVI clinic&#xD;
      visits, as well as the morning after PVI (hospital day 1).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 17, 2017</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Oxygen Consumption (VO2)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Assessed by cardiopulmonary stress testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary vein function</measure>
    <time_frame>1-4 weeks prior to PVI. Reassessed at 6 months post-PVI.</time_frame>
    <description>Change in pulmonary vein cross sectional area measured by resting cardiac MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Variability</measure>
    <time_frame>1-4 weeks prior to PVI. Reassessed at 1 day and 6 months post-PVI.</time_frame>
    <description>Time and frequency domain analysis of subjects heart rate variability using 5- minute protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Assessment of Athletic Performance</measure>
    <time_frame>1-4 weeks prior to PVI. Reassessed at 6 months post-PVI.</time_frame>
    <description>Measured by athlete-specific questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Athletes</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Catheter Ablation</condition>
  <arm_group>
    <arm_group_label>Pulmonary Vein Isolation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary Vein Isolation</intervention_name>
    <description>Standard antral pulmonary vein isolation using radiofrequency ablation catheters</description>
    <arm_group_label>Pulmonary Vein Isolation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Paroxysmal or Persistent AF&#xD;
&#xD;
          -  Endurance or highly trained athletes (&gt;3H training/week for &gt;10 yrs)&#xD;
&#xD;
          -  NSR at time of stress testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Structural Heart Disease; LVEF &lt;45%&#xD;
&#xD;
          -  Moderate or Severe Valvular disease&#xD;
&#xD;
          -  eGFR &lt; 30&#xD;
&#xD;
          -  Contraindication to MRI&#xD;
&#xD;
          -  Less than average functional capacity&#xD;
&#xD;
          -  Previous episode of AF of &gt;14 days duration&#xD;
&#xD;
          -  Previous pulmonary vein isolation&#xD;
&#xD;
          -  Imaging evidence of pulmonary vein stenosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan Baranowski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Calvo N, Mont L, Tamborero D, Berruezo A, Viola G, Guasch E, Nadal M, Andreu D, Vidal B, Sitges M, Brugada J. Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes. Europace. 2010 Jan;12(1):30-6. doi: 10.1093/europace/eup320.</citation>
    <PMID>19923171</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 20, 2017</study_first_submitted>
  <study_first_submitted_qc>July 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Bryan Baranowski</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation, Athletes, Pulmonary Vein Isolation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

